Oct142022

Antibody Persistence and Booster Response in Adolescents and Young Adults 4 and 7.5 Years After Immunization with 4CMenB Vaccine

Recent Publications

Data on duration of protection against invasive meningococcal disease post-vaccination with the recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB) are limited. We evaluated bactericidal activity persistence in adolescents/young adults up to 7.5 years post-primary vaccination with 4CMenB, and response to a booster dose compared with vaccine-naïve controls.  This open-label, multicentre study enrolled 15-24 year-old-previously vaccinated…

Read article
Oct142022

A New Fully Liquid Presentation of MenACWY-CRM Conjugate Vaccine: Results from a Multicentre, Randomised, Controlled, Observer-Blind Study

Recent Publications

The currently licensed quadrivalent MenACWY-CRM conjugate vaccine presentation consists of two vials (lyophilised MenA and liquid MenCWY) to be reconstituted before injection. A new fully liquid formulation in a single vial has been developed to further improve the vaccine presentation. Since the MenA structure is subject to hydrolytic degradation, this study was conducted to compare…

Read article
Aug122020

Act Fast: Protect Yourself Against Meningococcal Disease

Events and Seminars, Latest News

Many people have heard stories of families they know being severely impacted by meningococcal disease. Although rare, the consequences can be devastating, including death or serious long-term disabilities like brain damage, deafness or loss of limbs. Meningococcal disease is caused by bacteria strains called meningococcus (or Neisseria meningitidis). The bacteria cause the membranes that cover…

Read article